Specifically, FLT3 internal tandem duplications (FLT3ITD) are found in 30–40% of all patients with acute myeloid leukemia (AML) and are associated with poor clinical prognosis due to relapse after chemotherapy [1]. This evidence concerns the gene FLT3 and acute myeloid leukemia.